260 related articles for article (PubMed ID: 32399765)
1. Thrombocytosis and Thrombosis: Is There Really a Correlation?
Galvez C; Stein BL
Curr Hematol Malig Rep; 2020 Aug; 15(4):261-267. PubMed ID: 32399765
[TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases).
Randi ML; Stocco F; Rossi C; Tison T; Girolami A
J Med; 1991; 22(4-5):213-23. PubMed ID: 1787383
[TBL] [Abstract][Full Text] [Related]
5. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
7. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
8. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
9. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
10. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.
Kessler CM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):10-4. PubMed ID: 15190517
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytosis.
Selroos O
Acta Med Scand; 1973 May; 193(5):431-6. PubMed ID: 4717324
[No Abstract] [Full Text] [Related]
12. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
Hur JY; Choi N; Choi JH; Kim J; Won YW
Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
[TBL] [Abstract][Full Text] [Related]
13. The risk of thrombosis in essential thrombocythemia and polycythemia vera.
Pearson TC
Semin Oncol; 2002 Jun; 29(3 Suppl 10):16-21. PubMed ID: 12096353
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
15. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
16. Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: A single center's experience.
Lakhwani S; Pardina-Echevarría M; Arcas-Vega R; Díaz-Sánchez OR; Hernández-García MT; Raya JM
Rev Clin Esp (Barc); 2022 Mar; 222(3):169-173. PubMed ID: 34657827
[TBL] [Abstract][Full Text] [Related]
17. Thrombosis in myeloproliferative neoplasms.
Falanga A; Marchetti M
Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
[TBL] [Abstract][Full Text] [Related]
18. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
Ryningen A; Apelseth T; Hausken T; Bruserud Ø
Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytosis: too much of a good thing?
Schafer AI
Trans Am Clin Climatol Assoc; 2002; 113():68-76; discussion 76-7. PubMed ID: 12053719
[TBL] [Abstract][Full Text] [Related]
20. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]